FDA expedites review of Biogen's multiple sclerosis drug

07/8/2009 | American City Business Journals

The FDA granted fast-track designation to Biogen Idec's PEGylated interferon beta-1a, a multiple sclerosis medicine. The drug's potential to treat patients with only one or two injections a month might have been a factor in the agency's decision. Biogen plans on "working closely with the FDA to expedite the compound's development and review process," a company official said.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN